Investigational drug · Phase 3
IBI343
Also called: Arcotatug Tavatecan
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for CLDN18.2 Positive, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Primary Gastric Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
10
Any phase or sponsor naming "IBI343"
First trial start
2024
Jun 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI343", any sponsor or status.
Conditions studied
As listed on its trial records.
- CLDN18.2 Positive
- Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Primary Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Gastric/Gastroesophageal Junction Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer
Approved drugs for the same conditions: Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI343" as an intervention, largest first.
- A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsPivotal-lookingRecruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05458219 · 470 participants (planned) · Start Oct 26, 2022 · Primary completion Jun 30, 2027
Drug: IBI343; FOLFIRINOX/mFOLFIRINOX and 2 more · For: Locally Advanced Unresectable or Metastatic Solid Tumors
Sites: Austin, Texas; Irving, Texas; San Antonio, Texas · 39 sites in all
- A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)Pivotal-lookingActive, not recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06238843 · 464 participants · Start Jun 30, 2024 · Primary completion Dec 30, 2026
Drug: Irinotecan OR Paclitaxel or Trifluridine/tipiracil( FTD/TPI); IBI343 · For: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Bengbu, China; Hefei, China; Lu'an, China · 95 sites in all
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07483554 · 389 participants (planned) · Start Apr 20, 2026 · Primary completion Mar 31, 2028
Drug: IBI343,Gemcitabine, Albumin-bound Paclitaxel · For: CLDN18.2 Positive; Gastric/Gastroesophageal Junction Adenocarcinoma; Pancreatic Ductal Adenocarcinoma
Sites: Hangzhou, China
- A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)Pivotal-lookingRecruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07066098 · 201 participants (planned) · Start Jul 17, 2025 · Primary completion Jun 30, 2027
Drug: IBI343; Placebo · For: Pancreatic Cancer
Sites: Shanghai, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07483567 · 90 participants (planned) · Start Apr 17, 2026 · Primary completion Jun 30, 2030
Drug: IBI343,sintilimab,oxaliplatin,S-1; sintilimab,oxaliplatin,S-1 · For: CLDN18.2 Positive; Primary Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
Sites: Beijing, China
Zhejiang UniversityAcademic, hospital or other
NCT06770439 · 64 participants (planned) · Start Apr 18, 2025 · Primary completion Jan 2027
Drug: IBI343; Gemcitabine+Albumin-bound paclitaxel · For: Advanced Pancreatic Cancers
Sites: Hangzhou, China · 2 sites in all
Zhejiang Cancer HospitalAcademic, hospital or other
NCT07692750 · 56 participants (planned) · Start Apr 30, 2025 · Primary completion Jun 30, 2027
Drug: IBI343+ capecitabine; IBI343+Capecitabine+oxaliplatin · For: Advanced Pancreatic Cancer
Sites: Hangzhou, China
Ruijin HospitalAcademic, hospital or other
NCT07025889 · 55 participants (planned) · Start Jun 2, 2025 · Primary completion Jul 2027
Drug: IBI343; Sintilimab and 2 more · For: Gastric Cancer
Sites: Shanghai, China
- IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic CancerNot yet recruiting
Zhejiang UniversityAcademic, hospital or other
NCT07415525 · 40 participants (planned) · Start Feb 1, 2026 · Primary completion Dec 31, 2028
Drug: IBI343 · For: Pancreatic Cancer; Borderline Resectable Pancreatic Adenocarcinoma
Sites: Hangzhou, China
- Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction AdenocarcinomaStatus unknown
Harbin Medical UniversityAcademic, hospital or other
NCT06321913 · 25 participants (planned) · Start Mar 15, 2024 · Primary completion Dec 31, 2025
Drug: IBI343 combined with IBI308 · For: Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Newest research
PubMed records naming it or its code names, newest first.
- CLDN18.2 ADCs "A Real Step Forward" for Stomach Cancer.
· Cancer Discov 2026
- CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapy.
Katoh M, Katoh M · Front Mol Med 2026
- Antibody-Drug Conjugates in the Treatment of Esophageal Cancer.
Wu D, Chen W, Zhao Q, et al. · Curr Treat Options Oncol 2026
- Beyond Zolbetuximab: Next-Generation Targeting Strategies for CLDN18.2.
Sagawa T, Nagashima H, Fujikawa K · J Gastrointest Cancer 2026
- Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules.
Katoh M, Loriot Y, Nakayama I, et al. · Front Mol Med 2025
- CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.
Liu J, Yang J, Sun Y, et al. · Nat Med 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.